FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY ... - Amgen
WEBMay 16, 2024 · FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER. Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor. IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median ...
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
WEBTHOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
WEBAug 4, 2022 · Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease. Tavneos Adds to Amgen 's Decades-Long Leadership in Inflammation and Nephrology.
Amgen Seeks Expanded US Approval For Autoimmune Disease …
WEBJun 5, 2024 · On Wednesday, Amgen Inc (NASDAQ: AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna (inebilizumab-cdon) for Immunoglobulin G4-related disease, a...
Amgen Agrees to Acquire Horizon Therapeutics for $27.8 Billion
WEBDec 12, 2022 · Amgen Inc. AMGN -2.00% agreed to acquire Horizon Therapeutics PLC for $27.8 billion, marking the largest healthcare merger of the year.
Amgen dives deeper into rare disease drugs with $27.8 bln …
WEBDec 12, 2022 · Amgen shares dipped less than 1% to close at $276.78. With the deal, Amgen gains two fast-growing drugs, the thyroid eye disease treatment Tepezza and gout treatment Krystexxa.
Where Will Amgen Be in 5 Years? - Yahoo Finance
WEB3 hours ago · Amgen's October 2023 acquisition of Horizon Therapeutics for $28 billion in cash could pay off through the next five years. The most important asset it got from that transaction is Tepezza, a ...
Amgen (AMGN) Rises Higher Than Market: Key Facts - Yahoo …
WEB3 days ago · AMGN. Amgen (AMGN) ended the recent trading session at $335.26, demonstrating a +0.85% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0. ...
Amgen quarterly profit rises 15%, obesity drug trials are on track
WEBFeb 6 (Reuters) - Amgen (AMGN.O) on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of...
Where Will Amgen Be in 5 Years? - The Motley Fool
WEB14 hours ago · Biotech giant Amgen (AMGN 0.91%) has had a harsh reminder of that reality in recent years. Some of its most recent brand-new launches, especially the cancer drug Lumakras, have made paltry (at ...
Skip to content